If you have been reading about human growth hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== Types == Originally, seven such proteins were discovered. Of these, six (BMP2 through BMP7) belong to the Transforming growth factor beta superfamily of proteins. BMP1 is a metalloprotease. Since then, thirteen more BMPs, all of which are in the TGF-beta family, have been discovered, bringing the total to twenty. The current nomenclature only recognizes 13, as many others are put under the growth differentiation factor naming instead.
=== Mammals (including humans) === Hydroxyapatite is present in bones and teeth; bone is made primarily of HA crystals interspersed in a collagen matrix—65 to 70% of the mass of bone is HA. Similarly HA is 70 to 80% of the mass of dentin and enamel in teeth. In enamel, the matrix for HA is amelogenins and enamelins instead of collagen. Importantly, hydroxyapatite-coated orthopedic implants perform better in certain patients. For instance, for patients with steatotic liver disease hydroxyapatite-coated titanium has superior properties. Hence, the potential of hydroxyapatite in the engineering of biomaterials is considered substantial. Hydroxyapatite deposits in tendons around joints results in the medical condition calcific tendinitis. Hydroxyapatite is a constituent of calcium phosphate kidney stones.
Wood Professor of Anesthesiology and Critical Care at the Perelman School of Medicine at the University of Pennsylvania, and a professor of engineering at the University of Pennsylvania School of Engineering and Applied Science, travelled to the State Research Institute of Circulation Pathology (since 2008 called the Meshalkin National Medical Research Center), at Novosibirsk in Novosibirsk Oblast in Siberia, to visit anesthetist Dmitri Guvakov (now at the Penn State Milton S. Hershey Medical Center) carry out an operation on ten-year-old Lyuda Sudilovskaya Produced by Brian Kay, directed by Pauline Duffy, made by Yorkshire Television
== Quantification using spectrophotometry == The concentration of a certain protein in a sample may be determined using spectrophotometric procedures. The concentration of a protein can be determined by measuring the OD at 280 nm on a spectrophotometer, which can be used with a standard curve assay to quantify the presence of tryptophan, tyrosine, and phenylalanine. However, this method is not the most accurate because the composition of proteins can vary greatly and this method would not be able to quantify proteins that do not contain the aforementioned amino acids. This method is also inaccurate due to the possibility of nucleic acid contamination. Other more accurate spectrophotometric procedures for protein quantification include the Biuret, Lowry, BCA, and Bradford methods. An alternative method for label free protein quantification in clear liquid is cuvette-based SPR technique, that simultaneously measures the refractive index ranging 1.0 to 1.6 nD and concentration of the protein ranging from 0.5 μL to 2 mL in volume. This system consists of the calibrated optical filter with very high angular resolution and the interaction of light with this crystal forms a resonance at a wavelength which correlates to concentration and refractive index near the crystal.
==== Estrogenic and antiestrogenic activities ==== CPA does not bind to the estrogen receptors. Accordingly, pre-treatment with CPA does not block the retention of estradiol in the brain in mice. CPA has no estrogenic or direct antiestrogenic activity. However, CPA has been reported to produce weak estrogenic effects in rodents. In any case, CPA has prominent indirect antiestrogenic effects via its progestogenic activity. This includes PR-mediated antiestrogenic activity in certain tissues like the uterus and vagina as well as suppression of estrogen levels via its PR-mediated antigonadotropic activity. CPA also has indirect estrogenic activity in the breasts via its antiandrogenic activity, as androgens have strong functional antiestrogenic effects in this part of the body. This underlies the slight gynecomastia that can occur with CPA in men.
Sources: en.wikipedia.org
== Reception == Ben Rogers reviewed the Fat Duck for The Independent in 1996, before it had gained any Michelin stars. He discovered that Blumenthal was cooking foie gras in sherry to give it a nutty flavour, but Rogers was not sure if this was warranted. He praised a jambonneau of duck, but found the monkfish rubbery. He described the menu as "awkwardly written, badly punctuated, and at points quite impenetrable". After the Fat Duck received its first Michelin star, David Fingleton visited it for The Spectator in 1999, and found the experience "beyond reproach; unsullied pleasure from start to finish". In 2001, Terry Durack reviewed the Fat Duck for The Independent. He was initially hesitant, expecting tricks straight away, but was surprised to find a bowl of normal green olives on the table as he arrived. He did not enjoy a mustard ice cream in a red cabbage gazpacho soup, but described the restaurant as "great" and gave it a score of 17 out of 20. In 2004, following the third Michelin star, Jan Moir of The Daily Telegraph gave it a negative review, saying that "while many of the flavours are politely interesting, the relentless pappy textures of mousses and foams and creams and poached meats really begins to grate". She also found it overpriced, calling it the "Fat Profit". Matthew Fort reviewed the Fat Duck for The Guardian in 2005, and wrote that "there is no doubt that the Fat Duck is a great restaurant and Heston Blumenthal the most original and remarkable chef this country has ever produced". In The Times, A. A.
While some of the neutrons released from the fission of 238U are fast enough to induce another fission in 238U, most are not, meaning it can never achieve criticality. While there is a very small (albeit nonzero) chance of a thermal neutron inducing fission in 238U, neutron absorption is orders of magnitude more likely.
The term RAST became a colloquialism for all varieties of (in vitro allergy) tests. This is unfortunate because it is well recognized that there are well-performing tests and some that do not perform as well, yet they are all called RASTs, making it difficult to distinguish between them. For these reasons, it is now recommended that the use of RAST as a generic descriptor of these tests be abandoned. The updated version, the ImmunoCAP Specific IgE blood test, is the only specific IgE assay the Food and Drug Administration has approved to quantitatively report to its detection limit of 0.1 kU/L.
An alpha helix (or α-helix) is a sequence of amino acids in a protein that are twisted into a coil (a helix). The alpha helix is the most common structural arrangement in the secondary structure of proteins. It is also the most extreme type of local structure, and it is the local structure that is most easily predicted from a sequence of amino acids. The alpha helix has a right-handed helix conformation in which every backbone N−H group hydrogen bonds to the backbone C=O group of the amino acid that is four residues earlier in the protein sequence. The alpha helix is also commonly called a: Pauling–Corey–Branson α-helix (from the names of three scientists who described its structure) 3.613-helix because there are 3.6 amino acids in one ring, with 13 atoms being involved in the ring formed by the hydrogen bond (starting with amidic hydrogen and ending with carbonyl oxygen)
Sources: en.wikipedia.org
=== By mouth === The basic appeal of hypoglycemic agents by mouth is that most people would prefer a pill or an oral liquid to an injection. However, insulin is a peptide hormone, which is digested in the stomach and gut and in order to be effective at controlling blood sugar, cannot be taken orally in its current form. The potential market for an oral form of insulin is assumed to be enormous, thus many laboratories have attempted to devise ways of moving enough intact insulin from the gut to the portal vein to have a measurable effect on blood sugar. A number of derivatization and formulation strategies are currently being pursued to in an attempt to develop an orally available insulin. Many of these approaches employ nanoparticle delivery systems and several are being tested in clinical trials.
=== Bile Acids === One of the key characteristics that distinguishes Clostridium scindens from other members of this genus is its ability to metabolize primary bile acids. Bile acids are cholesterol-based substrates formed in the liver, stored in the gallbladder, and released into the duodenum upon the entry of food to help facilitate the absorption of lipids and lipid-soluble vitamins. Humans naturally produce conjugated primary bile acids, such as cholic acid and chenodeoxycholic acid, after which gut commensals like C. scindens convert them into unconjugated secondary bile acids, like deoxycholic acid and lithocholic acid respectively. Primary bile acids are conjugated to either taurine or glycine by the enzyme N-acyltransferase to allow export from the liver.
where Ra, Rb, Rc, Rd are the radii in the circles externally tangent to the sides a, b, c, d respectively and the extensions of the adjacent two sides for each side. Several more characterizations are known in the four subtriangles formed by the diagonals.
=== Glycolysis === When more R5P is needed than NADPH, R5P can be formed through glycolytic intermediates. Glucose 6-phosphate is converted to fructose 6-phosphate (F6P) and glyceraldehyde 3-phosphate (G3P) during glycolysis. Transketolase and transaldolase convert two molecules of F6P and one molecule of G3P to three molecules of R5P. During rapid cell growth, higher quantities of R5P and NADPH are needed for nucleotide and fatty acid synthesis, respectively. Glycolytic intermediates can be diverted toward the non-oxidative phase of PPP by the expression of the gene for pyruvate kinase isozyme, PKM. PKM creates a bottleneck in the glycolytic pathway, allowing intermediates to be utilized by the PPP to synthesize NADPH and R5P. This process is further enabled by triosephosphate isomerase inhibition by phosphoenolpyruvate, the PKM substrate.
=== Biofilm formation === The first step in the formation of biofilms is adhesion. The initial bacterial adhesion to surfaces involves the adhesin–receptor interactions. Certain polysaccharides, lipids and proteins in the matrix function as the adhesive agents. EPS also promotes cell–cell cohesion (including interspecies recognition) to facilitate microbial aggregation and biofilm formation. In general, the EPS-based matrix mediates biofilm assembly as follows. First, the EPS formation takes place at the site of adhesion, it will be either produced on bacterial surfaces or secreted on the surface of attachment, and form an initial polymeric matrix promoting microbial colonization and cell clustering. Next, continuous production of EPS further expands the matrix in 3 dimensions while forming a core of bacterial cells. The bacterial core provides a supporting framework, and facilitates the development of 3D clusters and aggregation of microcolonies. Studies on P. aeruginosa, B. subtilis, V. cholerae, and S. mutans suggested that the transition from initial cell clustering to microcolony appears to be conserved among different biofilm-forming model organisms. As an example, S. mutans produces an exoenzyme, called glucosyltransferase (Gtf), which synthesizes glucans in situ using host diet sugars as substrates. Gtfs even bind to the bacteria that do not synthesize Gtfs, and therefore, facilitate interspecies and interkingdom coadhesion.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.